A novel gelatin crosslinking method retards release of mulberry 1-deoxynojirimycin providing a prolonged hypoglycaemic effect

► Mulberry 1-deoxynojirimycin (DNJ) has therapeutic potency in the suppression of postprandial blood glucose. ► Several doses of DNJ are needed to achieve optimal therapeutic effect, due to its short half-life. ► A novel method was developed to retard DNJ release using gelatin crosslinked with transglutaminase. ► High effective DNJ entrapment, increased AUC and prolonged hypoglycaemic effects were observed in rats.